LOGO
LOGO

Will Annexon's Real-World Evidence On ANX005 Support Upcoming Regulatory Submission For GBS?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

In the United States, a rare disease is defined as one that impacts fewer than 200,000 individuals, and in the European Union, a disease is considered rare if it affects fewer than 1 in 2,000 people. Around 7,000 rare diseases have been identified, with Guillain-Barré Syndrome being one of them.

Guillain-Barré Syndrome (GBS) is a condition in which a person's immune system attacks the peripheral nerves. The nerve damage progresses rapidly, causing acute neuromuscular paralysis, and can lead to significant morbidity, disability, and even death. Every year, 22,000 people in the U.S. and Europe are hospitalized with GBS. Currently, there are no approved treatments for this condition in the U.S. Intravenous Immunoglobulin (IVIg) is used off-label to treat GBS.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.